4-MINUTE READ
In brief
$300B
The patient affordability gap in developed markets would be an estimated $300B by 2028.
30%
Almost 30% of US patients report not taking their medicine as prescribed due to cost.
R&D has a pivotal role to play
$6.7B
The cost of bringing a successful medicine to market is between $2.6B and $6.7B including the cost of capital and cost of failure.
7%
The rising ratio of R&D spend per each new treatment approved, has increased 7% per approval annually over the last ten years.
Biopharma should intensify their focus on three strategic plays: New Science portfolio, digital and data-led research, and faster, smarter development.
Driving billions to millions
$1.7B
Three strategic plays suggest savings of $1.2-1.7B per successful treatment.
$450M
Accenture’s model suggests it will create additional revenue opportunities of $150-450M.
Realizing value from transformation
1
Establishing enterprise-level strategy, budget, and oversight for strategic plays and enablers through redistribution of budget for the enterprise and tracking of value realization.
2
Creating asset-centered teams with the objective of delivering business and patient value. Companies will need to evolve how teams operate and align incentives to asset outcomes.
3
Assessing the current maturity of enabling capabilities and making coordinated cross-enterprise investments to be able to scale the strategic plays.
Biopharma companies are already in innovation mode. Now is the time to shift strategy and generate a new “future-fit” R&D organization.